Plasma miRNA combination serving as marker for diagnosing colorectal cancer liver metastasis

Plasma miRNA combination serving as marker for diagnosing colorectal cancer liver metastasis

The invention relates to a marker for diagnosing colorectal cancer liver metastasis. The marker comprises miR-96, miR-99b and let-7a in human plasma, wherein the expression quantity of miR-96 and let-7a in plasma of a colorectal cancer liver metastasis patient is increased; the expression quantity o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CHEN YI, NING SHUFANG, LIU HAIZHOU, LI JILIN, WEI WEN'E, ZHANG LITU
Format: Patent
Sprache:chi ; eng
Schlagworte:
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
COMPOSITIONS THEREOF
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
CULTURE MEDIA
ENZYMOLOGY
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROCESSES OF PREPARING SUCH COMPOSITIONS
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention relates to a marker for diagnosing colorectal cancer liver metastasis. The marker comprises miR-96, miR-99b and let-7a in human plasma, wherein the expression quantity of miR-96 and let-7a in plasma of a colorectal cancer liver metastasis patient is increased; the expression quantity of miR-99b in plasma of a colorectal cancer liver metastasis patient is reduced; expression changes of miR-96, miR-99b and let-7a in plasma can be used as a combination of markers for diagnosing colorectal cancer liver metastasis; miR-96, miR-99b and let-7a are determined as powerful diagnostic factors for separating a CRLM patient from a CRC patient. 本发明涉及一种诊断结直肠癌肝转移标志物，包括人血浆中的miR-96，miR-99b和let-7a，miR-96和let-7a在结直肠癌肝转移患者的血浆中表达量升高，miR-99b在结直肠癌肝转移患者的血浆中表达量降低，血浆中的miR-96，miR-99b和let-7a表达改变可以作为诊断结直肠癌肝转移的标志物的组合，miR-96，miR-99b和let-7a被确定为将CRLM患者与CRC患者分离的强有力的诊断因素。